Raj Ranjan Tiwari1, Khushnuma Wahabi2, Ahmad Perwez2, Zafar Iqbal Bhat2, Syed Shamimul Hasan3, Sundeep Singh Saluja4, Moshahid Alam Rizvi2. 1. Department of Biosciences, Genome Biology Laboratory, Jamia Millia Islamia, New Delhi, India;School of Sciences, Indira Gandhi National Open University (IGNOU), New Delhi, India. 2. Department of Biosciences, Genome Biology Laboratory, Jamia Millia Islamia, New Delhi, India. 3. School of Sciences, Indira Gandhi National Open University (IGNOU), New Delhi, India. 4. Department of Gastrointestinal Surgery, Govind Ballabh Pant Hospital, New Delhi, India.
Abstract
BACKGROUND/AIMS: Alterations in Parkin (PRKN) have been described in many cancers; however, the molecular mechanism that contributes to loss of Parkin expression in colorectal cancer (CRC) remains unclear. The aim of this study was to investigate the involvement of PRKN mutation and loss of heterozygosity (LOH) in loss of Parkin expression. To understand the role of PRKN in cancer progression, we also evaluated the association of Parkin expression with clinicopathological parameters in North Indian population. MATERIALS AND METHODS: We studied 219 CRC samples and their adjacent normal tissues (control) obtained from North Indian patients with CRC. The expression of Parkin was analyzed by immunohistochemistry (IHC). PRKN mutations were analyzed by single-stranded conformational polymorphism (SSCP) and sequencing. For loss of heterozygosity (LOH), we employed two intragenic, D6S305 and D6S1599, and one telomeric marker, D6S1008. RESULTS: In our study, we found four novel somatic mutations, namely, C166G, K413N, R420P (exon 4), and V425E (exon 11). Both mutation in Parkin (p = 0.0014) and LOH (p = 0.0140) were significantly associated with loss of Parkin expression. Additionally, Parkin mutations were not associated with the clinicopathological parameters of the patients. Furthermore, both, LOH in Parkin and Parkin expression were significantly correlated with different clinicopathological variables (p<0.05). CONCLUSION: Our results indicate that Parkin expression is not regulated by a single mechanism, but both mutation and LOH contribute to loss of Parkin expression. We also provide evidence of involvement of Parkin in metastasis and cancer progression. We, therefore, suggest Parkin as a potential prognostic marker and warrant further analysis in this direction.
BACKGROUND/AIMS: Alterations in Parkin (PRKN) have been described in many cancers; however, the molecular mechanism that contributes to loss of Parkin expression in colorectal cancer (CRC) remains unclear. The aim of this study was to investigate the involvement of PRKN mutation and loss of heterozygosity (LOH) in loss of Parkin expression. To understand the role of PRKN in cancer progression, we also evaluated the association of Parkin expression with clinicopathological parameters in North Indian population. MATERIALS AND METHODS: We studied 219 CRC samples and their adjacent normal tissues (control) obtained from North Indian patients with CRC. The expression of Parkin was analyzed by immunohistochemistry (IHC). PRKN mutations were analyzed by single-stranded conformational polymorphism (SSCP) and sequencing. For loss of heterozygosity (LOH), we employed two intragenic, D6S305 and D6S1599, and one telomeric marker, D6S1008. RESULTS: In our study, we found four novel somatic mutations, namely, C166G, K413N, R420P (exon 4), and V425E (exon 11). Both mutation in Parkin (p = 0.0014) and LOH (p = 0.0140) were significantly associated with loss of Parkin expression. Additionally, Parkin mutations were not associated with the clinicopathological parameters of the patients. Furthermore, both, LOH in Parkin and Parkin expression were significantly correlated with different clinicopathological variables (p<0.05). CONCLUSION: Our results indicate that Parkin expression is not regulated by a single mechanism, but both mutation and LOH contribute to loss of Parkin expression. We also provide evidence of involvement of Parkin in metastasis and cancer progression. We, therefore, suggest Parkin as a potential prognostic marker and warrant further analysis in this direction.
Authors: Yongxing Gong; Travis Ian Zack; Luc G T Morris; Kan Lin; Ellen Hukkelhoven; Radhika Raheja; I-Li Tan; Sevin Turcan; Selvaraju Veeriah; Shasha Meng; Agnes Viale; Steven E Schumacher; Perry Palmedo; Rameen Beroukhim; Timothy A Chan Journal: Nat Genet Date: 2014-05-04 Impact factor: 38.330
Authors: Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-03-01 Impact factor: 508.702
Authors: Rossano Cesari; Eric S Martin; George A Calin; Francesca Pentimalli; Roberta Bichi; Holly McAdams; Francesco Trapasso; Alessandra Drusco; Masayoshi Shimizu; Valeria Masciullo; Giuseppina D'Andrilli; Giovanni Scambia; Maria Cristina Picchio; Hansjuerg Alder; Andrew K Godwin; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2003-04-28 Impact factor: 11.205
Authors: Stacy R Denison; Fang Wang; Nicole A Becker; Birgitt Schüle; Norman Kock; Leslie A Phillips; Christine Klein; David I Smith Journal: Oncogene Date: 2003-11-13 Impact factor: 9.867
Authors: Jihyoun Jeon; Mengmeng Du; Robert E Schoen; Michael Hoffmeister; Polly A Newcomb; Sonja I Berndt; Bette Caan; Peter T Campbell; Andrew T Chan; Jenny Chang-Claude; Graham G Giles; Jian Gong; Tabitha A Harrison; Jeroen R Huyghe; Eric J Jacobs; Li Li; Yi Lin; Loïc Le Marchand; John D Potter; Conghui Qu; Stephanie A Bien; Niha Zubair; Robert J Macinnis; Daniel D Buchanan; John L Hopper; Yin Cao; Reiko Nishihara; Gad Rennert; Martha L Slattery; Duncan C Thomas; Michael O Woods; Ross L Prentice; Stephen B Gruber; Yingye Zheng; Hermann Brenner; Richard B Hayes; Emily White; Ulrike Peters; Li Hsu Journal: Gastroenterology Date: 2018-02-17 Impact factor: 33.883